Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.99 USD
-1.77 (-1.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $135.92 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NBIX 135.99 -1.77(-1.28%)
Will NBIX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for NBIX
Promising Outlook for Neurocrine’s NBI-‘845 in MDD Market Based on Strong Phase 2 Results and Competitive Positioning
Buy Rating Affirmed for Neurocrine on Promising Phase 2 SAVITRI Study Results
Maintaining Hold on Neurocrine Amid Promising Yet Uncertain Clinical Developments
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Neurocrine Biosciences upgraded at Wells Fargo on pipeline